📊 HYPR Key Takeaways
Is Hyperfine, Inc. (HYPR) a Good Investment?
Hyperfine demonstrates promising early-stage medical device fundamentals with 50.7% gross margins and strong balance sheet liquidity, but current operations are fundamentally unsustainable with -$8.6M operating losses on only $3.9M revenue and -$9M annual cash burn. The company requires 2-3x revenue acceleration while maintaining margins merely to approach operational breakeven, making near-term profitability highly improbable without transformative execution.
Modest revenue growth with ~50% gross margin is outweighed by extremely negative operating and net margins and sustained cash burn. Liquidity is solid and debt-free, but ~$29M annual FCF burn against $35M cash implies a limited runway and probable external funding needs. Without clear operating leverage and acceleration in demand, profitability remains distant.
Hyperfine, Inc. Key Strengths (HYPR)
- Healthy gross margin of 50.7% indicates viable product economics and market acceptance
- Strong balance sheet with $40.8M cash and moderate leverage (0.38x D/E ratio) providing 4-5 year financial runway
- Excellent liquidity position (5.52x current ratio, 4.90x quick ratio) reduces near-term default risk
- Revenue growth at 5.2% YoY demonstrates early traction in medical device commercialization
- Minimal CapEx needs ($242K) suggest asset-light business model post-commercialization
- Debt-free balance sheet
- Strong liquidity (current 4.34x; quick 3.73x)
- Attractive gross margin (~49.8%) suggesting product economics potential
HYPR Stock Risks: Hyperfine, Inc. Investment Risks
- Severe unprofitability with operating loss of -$8.6M against revenue of only $3.9M creates -219% operating margin
- Negative operating cash flow (-$9.0M) and free cash flow (-$9.2M) indicate company cannot self-sustain and requires continuous capital
- Revenue base is critically small; absolute growth insufficient to cover fixed operating expenses
- Medical device commercialization risk with long development cycles, regulatory dependencies, and unproven market penetration
- Cash burn rate ($9M annually) against total cash ($40.8M) limits runway without additional financing, diluting shareholders
- No visible path to profitability—current revenue trajectory would require years to generate sufficient gross profit to cover fixed costs
- Severe operating losses (operating margin -273%)
- High cash burn (FCF -$29.13M) implying short runway
- Low scale and modest growth (+5.2% YoY) heighten dilution/execution risk
Key Metrics to Watch
- Quarterly revenue growth rate—must accelerate well above 5.2% to justify burn rate
- Gross profit dollars and operating expense trends—critical to track path to operating leverage
- Operating cash flow trajectory—essential indicator of whether business model can move toward sustainability
- Cash runway duration—determines timeline before potential dilutive capital raise becomes necessary
- Revenue per unit/customer and ASP trends—validates whether product economics are strengthening or deteriorating
- Quarterly operating cash burn/FCF vs. cash balance (runway)
- Revenue growth rate and gross margin trend
Hyperfine, Inc. (HYPR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.52x current ratio provides a solid financial cushion.
HYPR Profit Margin, ROE & Profitability Analysis
HYPR vs Healthcare Sector: How Hyperfine, Inc. Compares
How Hyperfine, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Hyperfine, Inc. Stock Overvalued? HYPR Valuation Analysis 2026
Based on fundamental analysis, Hyperfine, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Hyperfine, Inc. Balance Sheet: HYPR Debt, Cash & Liquidity
HYPR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Hyperfine, Inc.'s revenue has grown significantly by 807% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.56 indicates the company is currently unprofitable.
HYPR Revenue Growth, EPS Growth & YoY Performance
HYPR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.1M | -$8.6M | $-0.09 |
| Q3 2025 | $3.4M | -$9.2M | $-0.14 |
| Q2 2025 | $2.7M | -$9.2M | $-0.12 |
| Q1 2025 | $2.1M | -$9.4M | $-0.12 |
| Q3 2024 | $2.3M | -$9.8M | $-0.14 |
| Q2 2024 | $3.4M | -$9.8M | $-0.14 |
| Q1 2024 | $2.6M | -$9.8M | $-0.14 |
| Q3 2023 | $2.3M | -$10.6M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Hyperfine, Inc. Dividends, Buybacks & Capital Allocation
HYPR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Hyperfine, Inc. (CIK: 0001833769)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HYPR
What is the AI rating for HYPR?
Hyperfine, Inc. (HYPR) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HYPR's key strengths?
Claude: Healthy gross margin of 50.7% indicates viable product economics and market acceptance. Strong balance sheet with $40.8M cash and moderate leverage (0.38x D/E ratio) providing 4-5 year financial runway. ChatGPT: Debt-free balance sheet. Strong liquidity (current 4.34x; quick 3.73x).
What are the risks of investing in HYPR?
Claude: Severe unprofitability with operating loss of -$8.6M against revenue of only $3.9M creates -219% operating margin. Negative operating cash flow (-$9.0M) and free cash flow (-$9.2M) indicate company cannot self-sustain and requires continuous capital. ChatGPT: Severe operating losses (operating margin -273%). High cash burn (FCF -$29.13M) implying short runway.
What is HYPR's revenue and growth?
Hyperfine, Inc. reported revenue of $3.9M.
Does HYPR pay dividends?
Hyperfine, Inc. does not currently pay dividends.
Where can I find HYPR SEC filings?
Official SEC filings for Hyperfine, Inc. (CIK: 0001833769) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HYPR's EPS?
Hyperfine, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is HYPR's fundamental grade?
Based on our AI fundamental analysis in May 2026, Hyperfine, Inc. has a C grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is HYPR stock overvalued or undervalued?
Valuation metrics for HYPR: ROE of -25.1% (sector avg: 15%), net margin of -220.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is HYPR's AI grade for 2026?
Our dual AI analysis gives Hyperfine, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HYPR's free cash flow?
Hyperfine, Inc.'s operating cash flow is $-9.0M, with capital expenditures of $242.0K. FCF margin is -237.0%.
How does HYPR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -220.9% (avg: 12%), ROE -25.1% (avg: 15%), current ratio 5.52 (avg: 2).